Increased homocysteine and decreased adenosine formation in Alzheimer's disease

Neurological Research

Volumn 26, Issue 5, 2004, Pages 554-557

  Selley, Michael L ^a  

^a Angiogen Pharmaceuticals Pty Ltd   (Australia)

Author keywords

Adenosine; Alzheimer's disease; Homocysteine; Stroke; Vascular disease

Indexed keywords

ADENOSINE; HOMOCYSTEINE; S ADENOSYLHOMOCYSTEINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYDROLYSIS; MALE; PATHOGENESIS; RISK FACTOR; STROKE; VASCULAR DISEASE;

ADENOSINE; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CEREBROVASCULAR DISORDERS; DOWN-REGULATION; FEMALE; HOMOCYSTEINE; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PREDICTIVE VALUE OF TESTS; S-ADENOSYLHOMOCYSTEINE; UP-REGULATION;

EID: 3042729591     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164104225016182     Document Type: Article

References (56)

1. 12 and serum total homocysteine levels in confirmed Alzheimer's disease. Arch Neurol 1998; 55: 1449-1455
2. McCaddon A, Davies G, Hudason P, et al. H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998; 13: 235-239
3. Miller JW. Homocysteine and Alzheimer's disease. Nutr Rev 1999; 57: 126-129
4. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-483
5. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-291
6. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. J Am Med Assoc 1995; 274: 1526-1533
7. Sutton-Tyrrell K, Bostom A, Selhub J, et al. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997; 96: 1745-1749
8. Meigs JB, Jacques PF, Selhub J, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome: The Framingham offspring study. Diabetes Care 2001; 24: 1403-1410
9. Drzewoski J, Czupryniak L, Chwatko G, et al. Hyperhomocysteinemia in poorly controlled type 2 diabetes patients. Diabetes Nutr Metab 2000; 13: 319-324
10. Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham study. Ann Intern Med 1999; 131: 352-355
11. Ay H, Arsava EM, Tokgozoglu SL, et al. Hyperhomocysteinemia is associated with the presence of left atrial thrombus in stroke patients with nonvalvular atrial fibrillation. Stroke 2003; 34: 909-912
12. Hofman H, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151-154
13. Kivipelto M, Helkala E-L, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. Br Med J 2001; 322: 1447-1451
14. Elias ME, Wolf PA, D'Agostino RB, et al. Untreated blood pressure level is inversely related to cognitive functioning: The Framington study. Am J Epidemiol 1993; 138: 353-364
15. Kuusisto J, Koivisto K, Mykkänen L, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: Cross sectional population based study. Br Med J 1997; 315: 1045-1049
16. Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53: 1937-1942
17. Honig LS, Tang MX, Albert S, et al. Stroke and the risk of Alzheimer's disease. Arch Neurol 2003; 60: 1707-1712
18. Ott A, Breteler MM, de Bruyne MC, et al. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997; 28: 316-321
19. Chen Y-F, Li P-L, Zou A-P. Effect of hyperhomocysteinemia on plasma or tissue adenosine levels and renal function. Circulation 2002; 106: 1275-1281
20. Riksen NP, Rongen GA, Blom HJ, et al. Potential role for adenosine in the pathogenesis of the vascular complications of hyperhomocysteinemia. Cardiovasc Res 2003; 59: 271-276
21. McKhan G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-944
22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd edn. Washington DC: American Psychiatric Press, 1994
23. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive status of patients for the clinician. J Psychiatr Res 1975; 12: 189-198
24. Rosen WG, Mohs RC, et al. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-1364
25. Magera MJ, Lacey JM, Casetta B, et al. Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry. Clin Chem 1999; 45: 1517-1522
26. Nithipatikom K, Mizumura T, Gross GJ. Determination of plasma adenosine by high-performance liquid chromatography with column switching and fluorometric detection. Anal Biochem 1994; 223: 280-284
27. de la Torre JC. Vascular basis of Alzheimer's pathogenesis. Ann NY Acad Sci 2002; 977: 196-215
28. Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging 2000; 21: 321-330
29. Berne RM, Rubio R, Curnish RR. Release of adenosine from ischemic brain. Effect on cerebral vascular resistance and incorporation into cerebral adenine nucleotides. Circ Res 1974; 35: 262-271
30. Coney AM, Marshall JM. Role of adenosine and its receptors in the vasodilatation induced in the cerebral cortex of the rat by systemic hypoxia. J Physiol 1998; 509: 507-518
31. Blood A, Hunter CJ, Power GG. The role of adenosine in regulation of cerebral blood flow during hypoxia in the near-term fetal sheep. J Physiol 2002; 543: 1015-1023
32. Van Wylen DG, Park TS, Rubio R, et al. Increases in cerebral interstitial fluid adenosine concentration during hypoxia, local potassium infusion, and ischemia. J Cereb Blood Flow Metab 1986; 6: 522-528
33. Hagberg H, Andersson P, Lacarewicz J, et al. Extracellular adenosine, inosine, hypoxanthine, and xanthine in relation to tissue nucleotides and purines in rat striatum during transient ischemia. J Neurochem 1987; 49: 227-231
34. Latini S, Bordoni F, Pedata F, et al. Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices. Br J Pharmacol 1999; 127: 729-739
35. 2a receptors in ischemia. Ann NY Acad Sci 2001; 939: 74-84
36. Sullivan GW, Sarembock IJ, Linden J. The role of inflammation in vascular diseases. J Leukoc Biol 2000; 67: 591-602
37. Cronstein BN, Kramer SB, Weissmann G, et al. Adenosine: A physiological modulator of superoxide anion generation by human neutrophils. J Exp Med 1983; 158: 1160-1177
38. 2 receptor on human neutrophils. J Immunol 1985; 135: 1366-1371
39. 2 receptors. J Immunol 1992; 148: 2201-2206
40. 2A receptors in human monoctic THP-1 cells. J Immunol 2001; 167: 4026-4032
41. Le Vraux V, Chen YL, Masson I, et al. Inhibition of human monocytic TNF production by adenosine receptor agonists. Life Sci 1993; 52: 1917-1924
42. 2 receptors, adenosine inhibits the production of tumor necrosis factor-α of endotoxin-stimulated human polymorphonuclear leukocytes. J Lab Clin Med 1995; 126: 275-282
43. 2A receptor-dependent and independent mechanisms. FASEB J 2000; 14: 2065-2074
44. Bouma MG, van den Wildenberg FA, Buurman WA. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol 1996; 270: C522-C529
45. Hasko G, Cronstein BN. Adenosine: An endogenous regulator of innate immunity. Trends Immunol 2004; 25: 33-39
46. Dubey R, Mi Z, Gillespie DG, et al. Dysregulation of extracellular adenosine levels by vascular smooth muscle cells from spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 2001; 21: 249-254
47. 2B receptors mediate antimitogenesis in vascular smooth muscle cells. Hypertension 2000; 35: 267-272
48. Dubey RK, Gillespie DG, Jackson EK. Adenosine inhibits collagen and total protein synthesis in vascular smooth muscle cells. Hypertension 1999; 33: 267-272
49. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer's disease. The Nun Study. J Am Med Assoc 1997; 277: 813-817
50. Edlund A, Siden A, Sollevi A. Evidence for an anti-aggregatory effect of adenosine at physiological concentrations and for its role in the action of dipyridamole. Thromb Res 1987; 45: 183-190
51. Cristalli G, Vittori S, Thompson RD, et al. Inhibition of platelet aggregation by adenosine receptor agonists. Naunyn Schmiedebergs Arch Pharmacol 1994; 349: 644-650
52. Deguchi H, Takeya H, Urano H, et al. Adenosine regulates tissue factor expression on endothelial cells. Thromb Res 1998; 91: 57-64
53. Minamino T, Kitakaze M, Asanuma H, et al. Endogenous adenosine inhibits P-selectin-dependent formation of coronary thromboemboli during hypoperfusion in dogs. J Clin Invest 1998; 101: 1643-1653
54. Minamino T, Kitakaze M, Asanuma H, et al. Plasma adenosine levels and platelet activation in patients with atrial fibrillation. Am J Cardiol 1999; 83: 194-198
55. Ohkubo T, Mitsumoto Y, Mohri T. Characterization of the uptake of adenosine by cultured rat hippocampal cells and inhibition of the uptake by xanthine derivatives. Neurosci Lett 1991; 133: 275-278
56. Kittner B, Rossner M, Rother M. Clinical trials in dementia with propentofylline. Ann NY Acad Sci 1997; 826: 307-316